Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Phase 2 Completed
17 enrolled 5 charts
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Phase 2 Completed
48 enrolled 12 charts
RGDLymphome
Phase 2 Completed
21 enrolled
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
Phase 2 Completed
45 enrolled 12 charts
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Phase 2 Completed
44 enrolled
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Phase 2 Completed
23 enrolled 15 charts
CBT-I in PBT
Phase 2 Completed
70 enrolled
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Phase 2 Completed
30 enrolled
LNH2007-3B
Phase 2 Completed
222 enrolled
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Phase 2 Completed
60 enrolled 15 charts
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Phase 2 Completed
110 enrolled 18 charts
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Phase 2 Completed
94 enrolled 20 charts
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
Phase 2 Completed
55 enrolled
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
11 enrolled 9 charts
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Phase 2 Completed
47 enrolled 8 charts
(CITADEL-205)
Phase 2 Completed
162 enrolled 18 charts
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Phase 2 Completed
3 enrolled 8 charts
CITADEL-203
Phase 2 Completed
126 enrolled 15 charts
Ixazomib Rollover Study
Phase 2 Completed
32 enrolled 13 charts
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Phase 2 Completed
104 enrolled 29 charts
BURGUND
Phase 2 Completed
115 enrolled
TRANSCENDWORLD
Phase 2 Completed
113 enrolled 35 charts
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Phase 2 Completed
42 enrolled 13 charts
Bretuximab
Phase 2 Completed
25 enrolled 12 charts
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Phase 2 Completed
19 enrolled 18 charts
AVAIL-T
Phase 2 Completed
35 enrolled 21 charts
TEAM
Phase 2 Completed
50 enrolled
PTCL
Phase 2 Completed
65 enrolled 16 charts
RAPID
Phase 2 Completed
124 enrolled 13 charts
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 2 Completed
117 enrolled 40 charts
Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb
Phase 2 Completed
91 enrolled
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
Phase 2 Completed
60 enrolled
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
Phase 2 Completed
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Phase 2 Completed
12 enrolled 21 charts
SPiReL
Phase 2 Completed
25 enrolled
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Phase 2 Completed
68 enrolled
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Phase 2 Completed
25 enrolled 10 charts
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
Phase 2 Completed
50 enrolled
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
44 enrolled
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 2 Completed
21 enrolled 11 charts
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase 2 Completed
105 enrolled 8 charts
Bortezomib in Treating Patients With Mantle Cell Lymphoma
Phase 2 Completed
30 enrolled
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Phase 2 Completed
29 enrolled
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase 2 Completed
91 enrolled 17 charts
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
Phase 2 Completed
22 enrolled 15 charts
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
100 enrolled 8 charts
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Phase 2 Completed
289 enrolled 34 charts